Notícias e Atividades da Revance Therapeutics

Revance Therapeutics pertence à Crown Laboratories.

Fusão, aquisição e financiamento envolvendo Crown Laboratories.

• Crown Laboratories adquiriu Revance Therapeutics (publicado em 9 de fevereiro de 2025).
• Revance Therapeutics has announced the acquisition of Revance Therapeutics  (publicado em 14 de janeiro de 2025).
• Crown Laboratories and Revance Therapeutics have announced they will merge  (publicado em 14 de agosto de 2024)..

Veja o organograma con seus 15 executivos principais

Biografias mais buscadas da Revance Therapeutics

• Mark Foley, President, Chief Executive Officer and Director
• Chris Nolet, Director
• Carey O'Connor Kolaja, Director

Recentes movimentos de executivos em Revance Therapeutics

• Tobin Schilke, Chief Financial Officer, deixou a Companhia  (Notícia publicada em 24 de fevereiro de 2025).

Recentes movimentos de executivos em Crown Laboratories

• Adelle Walker, ingressou na Companhia como Chief Marketing Officer, Aesthetics  (Notícia publicada em 28 de fevereiro de 2025).
• Adrianne Shapira, ingressou na Companhia como Director  (Notícia publicada em 21 de fevereiro de 2025).
• Satish Kalala, ingressou na Companhia como Chief Technology Officer  (Notícia publicada em 25 de outubro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Revance Therapeutics.

Crown Laboratories possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Revance Therapeutics

• Revance to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Revance Therapeutics, Inc.
• Revance To Present Clinical Data on DaxibotulinumtoxinA for Injection at the 2022 TOXINS International Conference - Revance Therapeutics, Inc.
• Revance to Participate in the William Blair 42nd Annual Growth Stock Conference - Revance Therapeutics, Inc.
• Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update - Revance Therapeutics, Inc.
• Revance to Release First Quarter Financial Results on Tuesday, May 10, 2022 - Revance Therapeutics, Inc.
• Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting - Revance Therapeutics, Inc.
• Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Revance Therapeutics, Inc.
• Revance to Participate in the Morgan Stanley 18th Annual Global Healthcare Conference - Revance Therapeutics, Inc.
• Revance to Participate in the Wells Fargo Securities Healthcare Conference - Revance Therapeutics, Inc.
• Revance Commercial Infrastructure Established and Positioned to Launch Prestige Aesthetics Portfolio with the RHA® Collection of Dermal Fillers - Revance Therapeutics, Inc.
• View more press releases Close

Redes sociais sobre Revance Therapeutics

• Revance Therapeutics na Wikipedia, Google News e Yahoo Finance
• Revance Therapeutics na LinkedIn, Twitter e YouTube